TriangleNCT05397171 · OUTCOME
Maximum Observed Concentration (Cmax) of AZD8853
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Micrograms per milliliter (ug/mL)
- Interval / dispersion
- Standard Deviation
- Time frame
- 0 hour, 15 minutes, 2 hours, 6 hours, 24 hours, 168 hours and 336 hours post EOI of Cycle 1 (each cycle equals to 21 days)
What was measured
The pharmacokinetic (PK) (Cmax) of AZD8853 in serum when administered in participants with selected advanced/metastatic solid tumors were assessed. This outcome measure was assessed only for substudy 1 Part A.
Analysis population: PK analysis set included all participants who received at least one dose of IP with at least one reportable concentration.
Groups in this outcome
AZD8853 300 mg
Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
AZD8853 1000 mg
Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
AZD8853 3000 mg
Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
| Group | Source count |
|---|---|
| AZD8853 300 mg | 3 |
| AZD8853 1000 mg | 6 |
| AZD8853 3000 mg | 7 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| AZD8853 300 mg | 76.70 | 3.439 | Not reported | Not reported | Not reported |
| AZD8853 1000 mg | 339.5 | 96.74 | Not reported | Not reported | Not reported |
| AZD8853 3000 mg | 1121 | 225.9 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 3.439
- value
- 76.70
- group Id
- OG001
- spread
- 96.74
- value
- 339.5
- group Id
- OG002
- spread
- 225.9
- value
- 1121
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 6
- group Id
- OG002
- value
- 7
- units
- Participants
- description
- The pharmacokinetic (PK) (Cmax) of AZD8853 in serum when administered in participants with selected advanced/metastatic solid tumors were assessed. This outcome measure was assessed only for substudy 1 Part A.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- OG000
- title
- AZD8853 300 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- OG001
- title
- AZD8853 1000 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- OG002
- title
- AZD8853 3000 mg
- param Type
- MEAN
- population Description
- PK analysis set included all participants who received at least one dose of IP with at least one reportable concentration.
- reporting Status
- POSTED
- time Frame
- 0 hour, 15 minutes, 2 hours, 6 hours, 24 hours, 168 hours and 336 hours post EOI of Cycle 1 (each cycle equals to 21 days)
- title
- Maximum Observed Concentration (Cmax) of AZD8853
- type
- SECONDARY
- unit Of Measure
- Micrograms per milliliter (ug/mL)
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice